Research programme: chitinase inhibitors - OncoArendi Therapeutics

Drug Profile

Research programme: chitinase inhibitors - OncoArendi Therapeutics

Alternative Names: AMCase inhibitors – OncoArendi Therapeutics; CHI3L1 modulators - OncoArendi Therapeutics; Chit1 modulators - OncoArendi Therapeutics; OATD 01

Latest Information Update: 23 Oct 2015

Price : $50

At a glance

  • Originator Yale University
  • Developer OncoArendi Therapeutics
  • Class Antiasthmatics; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Chitinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma

Most Recent Events

  • 13 Oct 2015 Preclinical trials in Asthma in Poland (PO)
  • 13 Oct 2015 OncoArendi acquires exclusive worldwide rights to AMCase targets and inhibitors, from the Yale University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top